- Home
- FCAP vs CHRS Comparison
FCAP vs CHRS Comparison
Compare FCAP & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FCAP
- CHRS
- Stock Information
- Founded
- FCAP 1891
- CHRS 2010
- Country
- FCAP United States
- CHRS United States
- Employees
- FCAP N/A
- CHRS N/A
- Industry
- FCAP Savings Institutions
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FCAP Finance
- CHRS Health Care
- Exchange
- FCAP Nasdaq
- CHRS Nasdaq
- Market Cap
- FCAP 115.2M
- CHRS 134.4M
- IPO Year
- FCAP 1999
- CHRS 2014
- Fundamental
- Price
- FCAP $35.99
- CHRS $1.07
- Analyst Decision
- FCAP
- CHRS Strong Buy
- Analyst Count
- FCAP 0
- CHRS 4
- Target Price
- FCAP N/A
- CHRS $5.38
- AVG Volume (30 Days)
- FCAP 2.4K
- CHRS 2.0M
- Earning Date
- FCAP 01-24-2025
- CHRS 03-12-2025
- Dividend Yield
- FCAP 3.22%
- CHRS N/A
- EPS Growth
- FCAP N/A
- CHRS N/A
- EPS
- FCAP 3.57
- CHRS N/A
- Revenue
- FCAP $41,997,000.00
- CHRS $304,340,000.00
- Revenue This Year
- FCAP N/A
- CHRS $2.07
- Revenue Next Year
- FCAP N/A
- CHRS N/A
- P/E Ratio
- FCAP $10.09
- CHRS N/A
- Revenue Growth
- FCAP 2.23
- CHRS 44.19
- 52 Week Low
- FCAP $26.73
- CHRS $0.66
- 52 Week High
- FCAP $38.00
- CHRS $2.65
- Technical
- Relative Strength Index (RSI)
- FCAP 72.77
- CHRS 39.03
- Support Level
- FCAP $33.55
- CHRS $1.06
- Resistance Level
- FCAP $36.48
- CHRS $1.16
- Average True Range (ATR)
- FCAP 0.81
- CHRS 0.08
- MACD
- FCAP 0.27
- CHRS 0.00
- Stochastic Oscillator
- FCAP 90.63
- CHRS 5.56
About FCAP First Capital Inc.
First Capital Inc is the financial holding company of First Harrison Bank. Through its subsidiary, it operates as a federally-chartered savings bank that provides banking services to individuals and business customers across locations in America. The bank offers various loans which include residential loans, construction loans, commercial real estate loans and commercial business loans. It also provides consumer loans such as home equity and second mortgage loans, and automobile and truck loans.
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.